Top

Intensive Care Medicine

Published in:

01-06-2012 | Correspondence

Less blood loss with tetrastarch?

Authors: Christiane S. Hartog, Konrad Reinhart

Published in: Intensive Care Medicine | Issue 6/2012

Excerpt

Dear Editor, …

Hartog CS, Reuter D, Loesche W, Hofmann M, Reinhart K (2011) Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review. Intensive Care Med 37:1725–1737. doi:10.1007/s00134-011-2385-z PubMedCrossRef

Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, Rodrigus I, Daper A, Trenchant A (2005) Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 101:629–634PubMedCrossRef

Hanart C, Khalife M, De Ville A, Otte F, De Hert S, Van der Linden P (2009) Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 37:696–701PubMedCrossRef

Faraoni D, De Villé A, Hofer A, Heschl M, Gombotz H, Van der Linden P. Efficacy and safety of 6 % HES 130/0.4 versus 5% HA for volume replacement during pediatric cardiac surgery. In: Abstract of the American Society of Anesthesiologists, Annual Meeting 2011. Available at: http://www.asaabstracts.com/strands/asaabstracts/abstract.htm;jsessionid=10E9DA4E0F0C2EF1088D49CDF6B4A0F9?year=2011&index=16&absnum=4705. Accessed 22 Dec 2011

James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS (2011) Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 107:693–702PubMedCrossRef

Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P (2008) The effects of hydroxyethyl starch 130/0.4 (6 %) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 107:382–390PubMedCrossRef

Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, Prough DS, Baus D, Bepperling F, Warltier DC (2007) Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 106:1120–1127PubMedCrossRef

Snapinn SM (2000) Noninferiority trials. Current controlled trials in Cardiovascular Medicine 1:19–21PubMedCrossRef

Hartog CS, Kohl M, Reinhart K (2011) A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 112:635–645PubMedCrossRef

10.

Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S (2011) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 114:159–169CrossRef

11.

de Jonge E, Levi M (2001) Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 29:1261–1267PubMedCrossRef

12.

Department of Health and Human Services, Food and Drug Administration (1998). List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. 21 CFR part 216 [Docket No. 98 –0655]. FDA, Washington D.C.

13.

Haynes GR, Havidich JE, Payne KJ (2004) Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 101:560–561PubMedCrossRef

14.

Hartog C, Brunkhorst F, Reinhart K (2009) Hydroxyethyl starch 130/0.4 and surgical blood loss. Anesth analg 108:672 (author reply 672–673)

15.

Replys. E-letter. Available at: http://bja.oxfordjournals.org/content/107/5/693/reply. Accessed 22 Dec 2011

Title: Less blood loss with tetrastarch?
Authors: Christiane S. Hartog
Konrad Reinhart
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 6/2012
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-012-2553-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Less blood loss with tetrastarch?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2012

Intensive care medicine: finding its way in the “European labyrinth”: reply to Van Aken et al.

Myeloid-derived suppressor cells in sepsis: friend or foe?

Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: a randomised trial

Coagulation Day 2010: an Austrian survey on the routine of thromboprophylaxis in intensive care

Technical problems with dynamic compliance evaluation in neonates and infants

Detecting pediatric delirium: development of a rapid observational assessment tool